Bahram Bodaghi
University of Paris
403 Papers
1.5K Citations
Bahram Bodaghi is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Uveitis. The author has an hindex of 51, co-authored 361 publications. Previous affiliations of Bahram Bodaghi include Pasteur Institute & French Institute of Health and Medical Research.
Chat about Author
Papers
Primary CNS lymphoma.
TL;DR: The diagnosis of primary CNS lymphoma (PCNSL) remains a challenge and is often delayed by several months and treatment options are still debated and the prognosis of PCNSL lymphoma is poor for most patients.
225
Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease
G. Geri,Benjamin Terrier,Michelle Rosenzwajg,Bertrand Wechsler,Maxime Touzot,Danielle Seilhean,Tu-Anh Tran,Bahram Bodaghi,Lucile Musset,Vassili Soumelis,David Klatzmann,Patrice Cacoub,David Saadoun +12 more
TL;DR: First evidence of the critical role of IL-21 in driving inflammatory lesions in BD is provided by promoting T(H)17 effectors and suppressing Treg cells in peripheral blood that correlate with BD activity.
223
Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease
Gulen Hatemi,Alan J. Silman,Dongsik Bang,Bahram Bodaghi,A. M Chamberlain,Ahmet Gül,M. H Houman,Ina Kötter,I. Olivieri,Carlo Salvarani,Petros P. Sfikakis,Aksel Siva,Miles Stanford,N. Stübiger,Sebahattin Yurdakul,Halil Yazici +15 more
TL;DR: Properly designed, controlled studies (new and confirmatory) are still needed to guide us in managing Behçet disease and controlled data for the management of vascular, gastrointestinal and neurological involvement is lacking.
214
Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients
H. Vallet,Sophie Rivière,Alice Sanna,Alban Deroux,Guillaume Moulis,Olga Addimanda,Carlo Salvarani,Marc Lambert,Philip Bielefeld,Pascal Sève,Jean Sibilia,Jl Pasquali,J.B. Fraison,Isabelle Marie,Laurent Perard,L. Bouillet,F. Cohen,Damien Sène,Yoland Schoindre,O Lidove,P. Le Hoang,Eric Hachulla,Olivier Fain,Xavier Mariette,Thomas Papo,Bertrand Wechsler,Bahram Bodaghi,M. Resche Rigon,Patrice Cacoub,D. Saadoun +29 more
TL;DR: Anti-TNF alpha therapy is efficient in all severe and refractory BD manifestations and appears to be similar regardless of the anti-T NF agent used (infliximab or adalimumab).
199